An experienced team delivering anti-cancer therapeutics with breakthrough potential

Karus Therapeutics is a clinical-stage biopharmaceutical company. We are developing precision medicines for cancer.

Our team

Our highly experienced management team has a track record of scientific and clinical excellence in small-molecule drug design and development. Our programs are underpinned by a broad, wholly-owned, intellectual property estate.

Our approach

Our orally-active small-molecule drugs have been designed and developed to be highly-selective therapies for cancer patients with unmet medical needs and limited treatment options.

Clinical Pipeline

We have two small molecule clinical candidates in Phase I studies, KA2507 and KA2237. By end-2019 we are planning to progress these to Phase II clinical trials. Pre-clinical data show that our innovative small-molecules have the potential to be used in combination with other therapies for the treatment of solid tumors and hematological cancers.


We invest in research and development of the highest quality and collaborate with leading academic centers of excellence. Our R&D program is focused on a new generation of brain-penetrant, non-genotoxic molecules targeting glioblastoma and other indications.

Strategic partnering

We seek strategic collaborations with leading companies who are commercializing innovative anti-cancer therapeutics.

Phase I clinical trials for KA22507 (NCT03008018) and KA2237 (NCT02679196) are currently underway in collaboration with The University of Texas MD Anderson Cancer Center.


We are supported by a syndicate of world-class life science investors from the US and Europe.